grant

Energizing and Protecting Axons Through Metabolic Coupling to Schwann Cells

Organization OHIO STATE UNIVERSITYLocation Columbus, UNITED STATESPosted 25 Jan 2023Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2024AccelerationAcuteAffectAnti-Cancer AgentsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsAnzataxAsotaxAxonBioenergeticsBiosensorBristaxolCancer DrugCausalityCell Communication and SignalingCell SignalingCessation of lifeChemotherapy-induced peripheral neuropathyCitric Acid CycleComplexCouplingCritical PathsCritical PathwaysCytoplasmDataDeathDecelerationDefectDegenerative Neurologic DisordersDevelopmentDiseaseDisorderDysfunctionElectron TransportEnergy ExpenditureEnergy MetabolismEnergy SupplyEnzyme GeneEnzymesEtiologyEventFailureFunctional disorderFutureGliaGlial CellsGlycolysisGoalsIatrogenic DiseaseImageInjuryIntracellular Communication and SignalingKolliker's reticulumKrebs CycleMeasuresMediatingMetabolicMitochondriaModelingMolecularMotorNeoplastic Disease Chemotherapeutic AgentsNerve CellsNerve DegenerationNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeurilemma CellNeurilemmal CellNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurogliaNeuroglial CellsNeurologic DeficitNeurologic Degenerative ConditionsNeurological disabilityNeuron DegenerationNeuronsNon-neuronal cellNonneuronal cellOligodendrocytesOligodendrocytusOligodendrogliaOligodendroglia CellPaclitaxelPaclitaxel (Taxol)PathologicPathway interactionsPatientsPeripheral Nervous SystemPersonalized medical approachPhysiologicPhysiologicalPhysiopathologyPositionPositioning AttributePraxelProcessProductionPublishingPyruvatePyruvate Dehydrogenase ComplexRespirationRoleSchwann CellsSignal TransductionSignal Transduction SystemsSignalingStereotypingStimulusTCA cycleTaxolTaxol ATaxol KonzentratTherapeuticThinkingTimeTricarboxylic Acid CycleTumor-Specific Treatment AgentsUp-RegulationUpregulationVertebrate AnimalsVertebratesWallerian DegenerationWorkafferent nerveanti-cancer drugaxon damageaxon injuryaxonal damageaxonal degenerationaxonal injuryaxonopathybiological sensorbiological signal transductioncausationcofactorcombatdegenerative axondegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdeprivationdevelopmentaldisease causationdisease modeldisorder modelelectron transferexhaustextracellularimagingimprovedin vivoindividualized approachinjuriesinjury responsemethyl pyruvatemitochondrialnerve cementneural cell bodyneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurological degenerationneuronalneuronal cell bodyneuronal degenerationnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpathophysiologypathwaypersonalized approachprecision approachprogramspyr translocatorpyruvate carrierpyruvate transport proteinpyruvate transporterrespiratoryrespiratory mechanismresponse to injurysecondary degenerationsensory nervesocial rolesomatailored approachtherapeutic targetthoughtstooluptakevertebrata
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Axons and their associated glia (Schwann cells and oligodendrocytes) form the largest part of the neuronal
network. Axons are challening to maintain energetically and are vulnerable to a wide spectrum of noxious stimuli.

Dysfunction of axons and pathological axon degeneration (pAxD) have emerged as a major pathophysiological

driver in many neurodegenerative diseases. Consequently, a central therapeutic focus is to develop approaches

tailored to protect axons. A prerequisite for such therapies is a better understanding of the autonomous and non-

cell autonomous molecular mechanisms that regulate the processes leading to pAxD. Physical disconnection of

the axon from the neuronal cell body is a widely-used experimental platform that has dramatically improved our

understanding of these processes over the last two decades. Primarily studied in the peripheral nervous system

of vertebrates, this paradigm triggers early injury responses in Schwann cells followed by rapid and stereotyped

disintegration of axons (Wallerian degeneration). It is now known that axon disintegration is evoked by a

conserved auto-destruction program that exhausts axonal ATP content through rapid depletion of the metabolic

cofactor NAD+ in disconnected axons. Importantly, recent studies indicate an instructive role of axonal

bioenergetics for the survival of injured axons. Given that neurodegenerative diseases are broadly associated

with axonal bioenergetic defects, these findings suggest that the decline of axonal bioenergetics occupies a

central position in the pathway leading to pAxD. In support of this, we recently made the exciting discovery that

Schwann cells convert their energy metabolism early upon axon injury to antagonize the structural breakdown

of injured axons, likely through the increased supply of glycolytic end-products (axon-glia metabolic coupling).

Furthermore, we found that the manipulation of the metabolic injury adaptation in Schwann cells accelerates or

delays the degeneration of perturbed axons in acute and subacute pAxD models. For the first time, this

demonstrates a non-cell-autonomous energetic mechanism that controls the fate of injured axons. The first aim

of this proposal attempts to determine if the suggested metabolic coupling mechanism counteracts the energetic

decline of injured axons through the enhanced supply of glial manocarboxylates that support axonal ATP

production. The next objective extends the identification of the key components of the metabolic coupling

pathway critical for the support of injured axons with an emphasis on axonal mitochondria. The final goal intends

to examine as to how manipulation of metabolic coupling influences pAxD in an iatrogenic disease model of

subacute axon pertubation. Collectively, this work has the potential to introduce a paradigm shift away from

neuron-centric views of axon protection. The proposed efforts may open the door for the future development of

novel therapeutic approaches taking into account the relationship between axonal and glial bioenergetics to

combat pAxD in neurodegenerative disorders.

.

Grant Number: 5R01NS123450-05
NIH Institute/Center: NIH

Principal Investigator: Elisabetta Babetto

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →